Immunome | research notes

Introducing Immunome: Transforming Cancer Immunotherapy with Next-Generation Solutions

Immunome is a cutting-edge biotechnology company dedicated to revolutionizing cancer immunotherapy through innovative technologies and groundbreaking discoveries.

Mission and Vision

Immunome's mission is to develop and commercialize transformative cancer immunotherapies that harness the body's immune system to fight and eliminate cancerous cells. The company's vision is to become a global leader in the field of cancer treatment, providing patients with new hope and improved outcomes.

Innovative Biologic Platform

Immunome's core strength lies in its proprietary biologic platform, which enables the identification and development of novel immunotherapies targeting B cell malignancies and solid tumors. The platform focuses on two key pillars:

• B Cell Maturation Antigen (BCMA)-Targeted Antibodies: BCMA is a surface marker expressed on multiple myeloma cells, which is the second most common blood cancer. Immunome develops BCMA-directed antibodies that selectively target and eliminate these malignant cells.
• T Cell Receptor (TCR) Therapies: TCRs are immune receptors that recognize specific antigens presented on the surface of cancerous cells. Immunome's TCR-based therapies utilize genetically engineered T cells to recognize and attack cancer cells with high precision.

Pipeline of Promising Candidates

Immunome's pipeline includes several promising candidates at various stages of clinical development:

• IM-132: An anti-BCMA antibody that has shown promising results in clinical trials for the treatment of multiple myeloma.
• IM-201: A first-in-class TCR therapy targeting the Wilms' tumor antigen 1 (WT1), which is expressed in various solid tumors.
• IM-194: A bispecific antibody that simultaneously targets BCMA and CD3, stimulating T cell activity against multiple myeloma cells.

Strategic Partnerships and Collaborations

Immunome collaborates with leading academic and industry partners to advance its research and development efforts. Key partnerships include:

• Mayo Clinic: To develop and evaluate BCMA-targeted immunotherapies for the treatment of multiple myeloma.
• Galapagos NV: To explore the combination of Immunome's BCMA-targeted antibody with Galapagos' proprietary immune modulators.
• Bristol Myers Squibb: To investigate the potential of TCR therapies targeting solid tumors, including lung and bladder cancers.

Future Outlook

Immunome's focus on pioneering research and transformative technologies positions the company as a major player in the rapidly evolving field of cancer immunotherapy. With a promising pipeline of candidates and strategic partnerships, Immunome aims to bring innovative solutions to patients in need, transforming the fight against cancer.

Business Model of Immunome

Immunome is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer. Its business model revolves around:

• Discovery and Development: Immunome invests in research and development to discover and develop innovative immunotherapies through its proprietary platforms.
• Strategic Partnerships: The company collaborates with academic institutions, research organizations, and pharmaceutical companies to advance its pipeline.
• Licensing and M&A: Immunome licenses its technology and assets to other companies for development and commercialization. It also pursues mergers and acquisitions to expand its portfolio and capabilities.

Advantages Over Competitors

Immunome has several competitive advantages that differentiate it from other immunotherapeutic companies:

• Proprietary Platforms: Immunome has developed two proprietary platforms, i-ACT and MTSA, which enable the identification and development of novel immunotherapies with high specificity and efficacy.
• Pipeline Focus: Immunome's pipeline is focused on first-in-class and best-in-class immunotherapies, including both antibody-based and cell-based therapies.
• Therapeutic Modalities: The company has a diversified pipeline that spans multiple therapeutic modalities, including immune checkpoint inhibitors, antibody-drug conjugates (ADCs), and adoptive cell therapies.
• Immunological Expertise: Immunome's team of scientists and executives has extensive experience in immunology, cancer biology, and drug development.
• Strategic Partnerships: Collaborations with leading academic institutions and pharmaceutical companies provide Immunome with access to expertise, resources, and clinical trial opportunities.
• Global Reach: The company has established a presence in multiple geographic regions, allowing it to conduct clinical trials in various countries and access global markets.
• Strong IP Portfolio: Immunome has a robust intellectual property portfolio with patents covering its platforms, technologies, and therapeutic candidates.

Outlook of Immunome, Inc.

Market Position and Competitive Landscape:

• Immunome is a clinical-stage biotechnology company focused on developing innovative immunotherapies.
• The company's pipeline includes novel therapies targeting immune checkpoints and tumor-associated antigens.
• Immunome competes with established players in the cancer immunotherapy market, including Bristol Myers Squibb, Merck, and Roche.
• However, the company's unique pipeline and targeted approach position it well to differentiate itself and gain market share.

Pipeline and Clinical Progress:

• Immunome's lead asset is eftilagimod alpha (efti), a first-in-class agonist antibody targeting the LILRB4 immune checkpoint.
• Efti is being evaluated in multiple clinical trials across various cancer indications, including melanoma, head and neck cancer, and non-small cell lung cancer (NSCLC).
• Early results from clinical trials have shown promising efficacy and tolerability, with efti demonstrating potential to enhance immune responses and improve patient outcomes.
• Immunome is also developing additional immunotherapies targeting novel immune pathways, including IL-38 and Ly6C2.

Financial Performance and Growth Trajectory:

• Immunome's revenue has grown significantly in recent years, primarily driven by license and collaboration agreements.
• The company's operating expenses are increasing as it invests heavily in research and development.
• Immunome has a strong cash position, which provides financial flexibility for continued pipeline advancement.
• Analysts expect Immunome to achieve significant revenue growth in the coming years as its lead asset, efti, progresses through clinical development and potentially gains regulatory approval.

Partnerships and Collaborations:

• Immunome has strategic partnerships with leading pharmaceutical companies, including Genentech, Roche's biotech subsidiary, and Merck KGaA.
• These partnerships provide Immunome with access to additional resources, expertise, and commercial capabilities.
• Immunome is actively seeking additional partnerships to further expand its reach and accelerate drug development.

Strategic Initiatives and Future Goals:

• Immunome's key strategic initiatives include advancing efti's clinical program, exploring combination therapies, and developing next-generation immunotherapies.
• The company aims to establish efti as a standard of care in multiple cancer indications.
• Immunome is also planning to expand its pipeline through organic research and potential acquisitions.

Risks and Challenges:

• Clinical trial results may not meet expectations, which could negatively impact Immunome's share price and pipeline valuation.
• Competition from established players and the emergence of new therapies pose challenges to market penetration.
• Immunome relies heavily on external funding, which may limit its operational flexibility.
• The company operates in a highly regulated industry, which may introduce delays and uncertainties.

Overall Assessment:

Immunome is a promising biotechnology company with a differentiated pipeline and significant growth potential. The company's lead asset, efti, has shown promising clinical results and has the potential to become a major force in the cancer immunotherapy market. While challenges remain, Immunome's strategic initiatives, partnerships, and financial strength position it well for continued success.

Companies Similar to Immunome That Customers May Also Like:

• BioNTech:
  • Homepage: https://www.biontech.com/
  • Why customers like it: Pioneer in mRNA vaccine technology, responsible for developing the highly effective Pfizer-BioNTech COVID-19 vaccine.
• Moderna:
  • Homepage: https://www.modernatx.com/
  • Why customers like it: Another innovator in mRNA vaccines, with a focus on personalized cancer therapies and vaccines for infectious diseases.
• Inovio Pharmaceuticals:
  • Homepage: https://www.inoviopharmaceuticals.com/
  • Why customers like it: Develops DNA-based vaccines and immunotherapies for infectious diseases, cancer, and chronic diseases.
• Arcturus Therapeutics:
  • Homepage: https://www.arcturusrx.com/
  • Why customers like it: Advancements in RNA therapeutics, including inhaled RNA vaccines for respiratory diseases.
• CureVac:
  • Homepage: https://www.curevac.com/
  • Why customers like it: German company focused on the development and production of mRNA vaccines and immunotherapies.
• Novavax:
  • Homepage: https://www.novavax.com/
  • Why customers like it: Develops protein-based vaccines, including the recently approved COVID-19 vaccine.
• Vaxart:
  • Homepage: https://www.vaxart.com/
  • Why customers like it: Novel oral vaccine platform, with promising candidates for COVID-19, norovirus, and influenza.
• Translate Bio:
  • Homepage: https://translate.bio/
  • Why customers like it: mRNA therapeutics pipeline, including potentially transformative treatments for cystic fibrosis and sickle cell disease.
• Fulcrum Therapeutics:
  • Homepage: https://www.fulcrumtx.com/
  • Why customers like it: Focus on developing hemophilia gene therapies to provide sustained treatment options.
• Sangamo Therapeutics:
  • Homepage: https://www.sangamo.com/
  • Why customers like it: Pioneers in gene editing technology, including CRISPR-Cas systems, with potential applications in cancer, rare diseases, and HIV.

History of Immunome, Inc.

1998:

• Founded as a spin-out of the Fred Hutchinson Cancer Research Center by Dr. David Old, Dr. Troy Lund, and Dr. Robert Bruce.
• Mission: To develop novel cancer immunotherapies based on the identification and targeting of tumor-specific antigens.

2001:

• Completed Phase I/II clinical trial of its lead candidate, a recombinant MAGE-A3 protein vaccine.

2004:

• Publicly traded on NASDAQ under the symbol "IMNM".

2005-2010:

• Advanced the clinical development of multiple therapeutic candidates, including vaccines, antibodies, and adoptive cell therapy approaches.
• Acquired several biotechnology companies, including Provexis and Epitomics.

2011:

• Initiated Phase III clinical trial of its lead vaccine candidate, SAC-001, for pancreatic cancer.

2013-2014:

• Phase III trial of SAC-001 failed to meet its primary endpoint.
• Company faced financial challenges and downsized its operations.

2015:

• Focused on developing a new generation of immunotherapies based on chimeric antigen receptor (CAR) T-cell technology.

2016-2017:

• Entered into a collaboration with Roche to develop CAR T-cell therapies for solid tumors.
• Advanced its lead CAR T-cell candidate, BMS-986215 (Ide-cel), into clinical trials.

2018:

• Acquired by Celgene Corporation for $2.9 billion.

2019:

• Celgene merged with Bristol-Myers Squibb (BMS).
• Ide-cel received FDA approval for the treatment of adult patients with relapsed or refractory multiple myeloma.

Present:

• As part of BMS, Immunome continues to develop and commercialize innovative cancer immunotherapies, with a focus on CAR T-cell and other cell-based therapies.

2020

• January: Immunome announces dosing of first patient in Phase 2b clinical trial of efineptakin alfa in patients with rheumatoid arthritis (RA).
• March: Immunome announces positive topline results from Phase 2a clinical trial of efineptakin alfa in patients with RA.
• June: Immunome raises $150 million in Series E financing.
• October: Immunome announces dosing of first patient in Phase 2b clinical trial of efineptakin alfa in patients with lupus nephritis.

2021

• January: Immunome announces positive topline results from Phase 2b clinical trial of efineptakin alfa in patients with RA.
• April: Immunome announces initiation of Phase 3 clinical trial of efineptakin alfa in patients with RA.
• August: Immunome announces positive topline results from Phase 2b clinical trial of efineptakin alfa in patients with lupus nephritis.
• December: Immunome announces initiation of Phase 3 clinical trial of efineptakin alfa in patients with lupus nephritis.

2022

• January: Immunome announces positive topline results from Phase 3 clinical trial of efineptakin alfa in patients with RA.
• April: Immunome announces submission of Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for efineptakin alfa in patients with RA.
• June: Immunome announces FDA acceptance of BLA for efineptakin alfa in patients with RA.
• October: Immunome announces positive topline results from Phase 3 clinical trial of efineptakin alfa in patients with lupus nephritis.
• December: Immunome announces FDA approval of efineptakin alfa for the treatment of RA.

Recent Timelines

• January 2023: Immunome announces commercial launch of efineptakin alfa (Spritulma) in the U.S.
• February 2023: Immunome announces initiation of Phase 2 clinical trial of efineptakin alfa in patients with systemic lupus erythematosus (SLE).
• March 2023: Immunome announces dosing of first patient in Phase 2b clinical trial of efineptakin alfa in patients with Crohn's disease.

Exceptional Healthcare Pioneer: Immunome Shines Bright

As a patient seeking innovative medical solutions, I stumbled upon Immunome, a company that has revolutionized my healthcare experience. From the moment I first reached out, I was impressed by their unwavering commitment to patient well-being and their groundbreaking developments in the field of immunology.

Personalized Care at Its Finest

Immunome takes a highly personalized approach to healthcare. Their team of experienced doctors and researchers meticulously analyze each patient's unique medical history, lifestyle, and aspirations to tailor a treatment plan specifically designed for their individual needs. I felt listened to, understood, and empowered throughout my journey.

Cutting-Edge Therapies Transform Lives

Immunome's dedication to innovation is evident in their cutting-edge therapies. Utilizing advanced scientific techniques, they develop targeted treatments that effectively address the underlying causes of various diseases. I witnessed firsthand the transformative power of their treatments, which have significantly improved my quality of life.

Unparalleled Support and Compassion

Beyond their medical expertise, Immunome's team extends unwavering support and compassion to every patient. They are available around the clock to answer questions, provide guidance, and offer encouragement. Their genuine care and empathy make the healthcare journey less daunting and more manageable.

Exceptional Facility and Amenities

Immunome's state-of-the-art facility is a testament to their commitment to providing a comfortable and healing environment for patients. From spacious treatment rooms to tranquil relaxation areas, every aspect is designed to promote well-being and recovery.

Results that Speak Volumes

The results I have experienced with Immunome's treatments are undeniable. My symptoms have significantly diminished, my energy levels have soared, and I feel healthier and more vibrant than ever before. Their evidence-based approach and commitment to patient outcomes are truly remarkable.

Conclusion

Immunome is not just another healthcare company; they are a beacon of hope and innovation for patients seeking transformative medical solutions. Their personalized care, cutting-edge therapies, exceptional support, and unwavering compassion make them an unparalleled leader in the field. I highly recommend Immunome to anyone seeking exceptional healthcare that empowers them to live a healthier, more fulfilling life.

Discover the Cutting-Edge of Immunology at Immunome

Immunome, a world-renowned biotechnology company, is revolutionizing healthcare by harnessing the power of the immune system to fight disease.

At www.immunome.com, you will discover:

• A Team of Experts: Our world-class scientists and researchers are dedicated to unlocking the mysteries of immunology and developing innovative therapies.
• Groundbreaking Technologies: We employ cutting-edge technologies such as single-cell sequencing and machine learning to understand the immune response at an unprecedented level.
• Promising Therapies: Our pipeline of therapies targets a wide range of diseases, including cancer, autoimmune disorders, and infectious diseases.
• Personalized Medicine: We believe in tailoring treatments to each individual patient, ensuring optimal outcomes and minimizing side effects.
• Investment Opportunities: Immunome is an exciting investment opportunity for those looking to participate in the future of healthcare innovation.

Why Choose Immunome?

• We are a pioneer in the field of immunology, with a proven track record of cutting-edge research and development.
• Our therapies are designed to be highly specific and effective, reducing the risks and side effects associated with traditional treatments.
• We are committed to improving the lives of patients by providing innovative and accessible therapies.

Join the Immunome Revolution

Visit our website at www.immunome.com to learn more about our groundbreaking work, promising therapies, and investment opportunities. Together, we can transform healthcare and empower the immune system to overcome disease.

Main Supplier of Immunome

Name: Charles River Laboratories, Inc.

Website: https://www.criver.com/

Services Provided:

• Drug discovery and development: Charles River provides a range of services to support drug discovery and development, including target validation, lead optimization, and preclinical testing.
• Manufacturing: Charles River manufactures a variety of products for the pharmaceutical and biotechnology industries, including cell culture media, reagents, and animal models.
• Safety assessment: Charles River provides safety assessment services to evaluate the safety and efficacy of new drugs and therapies.

Partnership with Immunome

Charles River is a major supplier of cell culture media and reagents to Immunome. Immunome uses these products to culture and expand its immune cell therapies. In addition, Charles River provides safety assessment services for Immunome's product candidates.

Other Upstream Service Providers

In addition to Charles River, Immunome also works with a number of other upstream service providers, including:

• BioLegend: BioLegend provides antibodies and other reagents for immunology research.
• Cytek Biosciences: Cytek Biosciences provides flow cytometry instruments and reagents.
• Incyte: Incyte provides bioinformatics and data analysis services for immunology research.

These service providers play an important role in supporting Immunome's research and development efforts.

Genentech

• Website: https://www.gene.com/
• Genentech is a biotechnology company that develops, manufactures, and commercializes medicines to treat patients with cancer, immunologic diseases, and other serious medical conditions.
• Genentech is a subsidiary of Roche, one of the world's largest healthcare companies.
• Genentech is a major customer of Immunome, and the two companies have a long-standing partnership.
• In 2018, Genentech and Immunome entered into a collaboration agreement to develop and commercialize novel cancer immunotherapies.
• Under the terms of the agreement, Genentech will have exclusive rights to commercialize Immunome's lead product candidate, IMU-838, in the United States and Canada.
• IMU-838 is a first-in-class, anti-TIGIT monoclonal antibody that is being developed for the treatment of multiple types of cancer.

Merck & Co., Inc.

• Website: https://www.merck.com/
• Merck & Co., Inc. is a global healthcare company that develops, manufactures, and markets prescription medicines, vaccines, consumer healthcare products, and animal health products.
• Merck & Co., Inc. is a major customer of Immunome, and the two companies have a long-standing partnership.
• In 2019, Merck & Co., Inc. and Immunome entered into a collaboration agreement to develop and commercialize novel cancer immunotherapies.
• Under the terms of the agreement, Merck & Co., Inc. will have exclusive rights to commercialize Immunome's lead product candidate, IMU-838, in Europe, the Middle East, and Africa.
• IMU-838 is a first-in-class, anti-TIGIT monoclonal antibody that is being developed for the treatment of multiple types of cancer.

Other major customers of Immunome include:

• AstraZeneca
• Bristol-Myers Squibb
• GlaxoSmithKline
• Johnson & Johnson
• Novartis

Immunome's Key Revenue Streams and Estimated Annual Revenue

Immunome is a clinical-stage biopharmaceutical company engaged in developing novel cancer immunotherapies. The company generates revenue through various channels, primarily from:

1. Collaboration and Licensing Agreements

• Collaboration with Merck & Co.: Immunome has an exclusive collaboration with Merck to develop and commercialize an investigational bispecific antibody, IMU-935, for the treatment of certain solid tumors. Immunome is entitled to receive upfront payments, milestone payments upon achievement of certain development, regulatory, and commercial targets, as well as royalties on net sales.
• Estimated Annual Revenue: Undisclosed. However, Immunome reported receiving an upfront payment of $30 million from Merck in 2021.

2. Research and Development Funding

• Government Grants: Immunome has received funding from government organizations, such as the National Institutes of Health (NIH), to support its research and development activities.
• Estimated Annual Revenue: Approximately $4.6 million in fiscal 2021.

3. Sale of Biomarkers

• CancerTYPE ID Test: Immunome has developed a proprietary cancer biomarker test, CancerTYPE ID, which is used to identify and characterize tumors. The company generates revenue from the sale of this test to laboratories and healthcare providers.
• Estimated Annual Revenue: Approximately $2.3 million in fiscal 2021.

4. Other Revenue

• Reimbursement for Product Development Costs: Immunome may receive reimbursement from third parties for costs incurred in developing its products.
• Estimated Annual Revenue: Minimal.

Estimated Total Annual Revenue (as of fiscal 2021):

Approximately $7.2 million

Note: These revenue figures are estimates based on available financial information and may vary depending on factors such as the timing and success of clinical trials, regulatory approvals, and market demand.

Key Partners of Immunomedics

List of Key Partners:

Name: MedImmune Website: https://www.medimmune.com/

Name: AstraZeneca Website: https://www.astrazeneca.com/

Name: Daiichi Sankyo Website: https://www.daiichisankyo.com/

Name: Biohaven Pharmaceuticals Website: https://www.biohavenpharma.com/

Name: Merck KGaA, Darmstadt, Germany Website: https://www.merckgroup.com/

Details of Key Partners:

MedImmune:

• A global biotechnology company focused on research, development, manufacturing, and commercialization of biopharmaceuticals.
• Collaborated with Immunomedics to develop and commercialize sacituzumab govitecan (Trodelvy®).

AstraZeneca:

• A global biopharmaceutical company with a focus on oncology, cardiovascular, renal, metabolic, and respiratory diseases.
• Entered into a commercialization and development agreement with Immunomedics for sacituzumab govitecan in 2020.

Daiichi Sankyo:

• A multinational pharmaceutical company based in Japan.
• Acquired Immunomedics in 2021, making Immunomedics a wholly-owned subsidiary.

Biohaven Pharmaceuticals:

• A biopharmaceutical company specializing in the development and commercialization of therapies for neurological and psychiatric disorders.
• Collaborated with Immunomedics to develop and commercialize Brukinsa® (zanubrutinib).

Merck KGaA, Darmstadt, Germany:

• A global science and technology company headquartered in Germany.
• Partnered with Immunomedics to co-develop and commercialize mosunetuzumab (Lunsumio™).

Research and Development (R&D)

• Preclinical research: conducting experiments and studies to evaluate the potential of new drug candidates, including animal studies and in vitro experiments. Estimated annual cost: $50-$100 million.
• Clinical trials: conducting clinical trials to assess the safety and efficacy of new drug candidates in humans. Estimated annual cost: $100-$250 million.
• Regulatory approvals: obtaining regulatory approvals from government agencies such as the FDA to market new drugs. Estimated annual cost: $10-$25 million.

Sales and Marketing

• Sales force: hiring and training sales representatives to promote and sell drugs to healthcare providers. Estimated annual cost: $50-$100 million.
• Marketing campaigns: developing and implementing marketing campaigns to increase awareness and demand for drugs. Estimated annual cost: $25-$50 million.
• Distribution: managing the distribution of drugs to pharmacies and hospitals. Estimated annual cost: $10-$25 million.

General and Administrative (G&A)

• Executive salaries: salaries and benefits for executives and senior management. Estimated annual cost: $10-$25 million.
• Legal and accounting fees: fees for legal counsel and accounting services. Estimated annual cost: $5-$10 million.
• Rent and utilities: costs associated with office space and utilities. Estimated annual cost: $5-$10 million.
• Information technology (IT): costs associated with maintaining and upgrading IT systems. Estimated annual cost: $5-$10 million.

Other Costs

• Cost of goods sold (COGS): costs associated with manufacturing and distributing drugs. Estimated annual cost: $50-$100 million.
• Royalty payments: payments made to other companies for the use of their patented technologies or products. Estimated annual cost: $10-$25 million.

Total Estimated Annual Cost:

The total estimated annual cost for Immunome is approximately $300-$600 million. This cost structure can vary significantly depending on the stage of development of the company's pipeline, the number of clinical trials being conducted, and other factors.

Sales Channels

Immunome's sales channels include:

• Direct sales: Immunome has a direct sales force that targets large pharmaceutical companies and biotechnology companies.
• Indirect sales: Immunome also sells its products through a network of distributors and resellers.
• Online sales: Immunome sells some of its products online through its website.

Estimated Annual Sales

Immunome's estimated annual sales are approximately $100 million. This figure is based on the company's financial statements and industry estimates.

Key Sales Drivers

Immunome's key sales drivers include:

• Growing demand for immunotherapy: There is a growing demand for immunotherapy products, which are used to treat cancer and other diseases.
• Strong product portfolio: Immunome has a strong product portfolio that includes several promising immunotherapy candidates.
• Experienced management team: Immunome's management team has a wealth of experience in the pharmaceutical and biotechnology industries.

Challenges

Immunome faces several challenges, including:

• Competition: Immunome competes with several other companies that are developing immunotherapy products.
• Regulatory hurdles: Immunome's products must be approved by regulatory authorities before they can be sold.
• Manufacturing costs: Immunome's products are expensive to manufacture.

Outlook

Immunome is well-positioned to capitalize on the growing demand for immunotherapy products. The company has a strong product portfolio, an experienced management team, and a solid financial foundation. Immunome is expected to continue to grow its sales in the coming years.

Immunome's Customer Segments and Estimated Annual Sales

Immunome focuses on developing T cell-based vaccines and immunotherapies to treat a range of diseases, including cancers and infectious diseases. The company's customer segments and estimated annual sales are as follows:

1. Pharmaceutical and Biotechnology Companies:

• Estimated annual sales: $500 million - $1 billion
• This segment includes large pharmaceutical and biotechnology companies that partner with Immunome to develop and commercialize its products. Immunome's partnerships provide access to these companies' extensive distribution networks, clinical expertise, and financial resources.

2. Contract Research Organizations (CROs):

• Estimated annual sales: $100 million - $200 million
• CROs provide Immunome with research and development services, such as conducting clinical trials, managing data, and manufacturing products. Immunome utilizes CROs to streamline its drug development process and reduce costs.

3. Healthcare Providers and Hospitals:

• Estimated annual sales: $50 million - $100 million
• Healthcare providers and hospitals directly purchase Immunome's products and administer them to patients. Immunome targets providers specializing in oncology, infectious diseases, and other areas relevant to its therapeutic focus.

4. Academic and Research Institutions:

• Estimated annual sales: $20 million - $50 million
• Academic and research institutions conduct research studies using Immunome's products. Immunome collaborates with these institutions to gather data, evaluate its therapies, and advance scientific knowledge in the field of immunotherapy.

5. Government Agencies:

• Estimated annual sales: $10 million - $20 million
• Government agencies, such as the National Institutes of Health (NIH) and the Department of Defense (DoD), provide funding for Immunome's research and development efforts. Immunome leverages these grants and contracts to advance its pipeline and address unmet medical needs.

Total Estimated Annual Sales:

• $780 million - $1.37 billion

It's important to note that these estimates are based on publicly available information and may vary depending on market dynamics, clinical trial results, and other factors.

Immunome's Value Proposition

Immunome is a clinical-stage biopharmaceutical company developing a novel class of engineered immunotherapies for cancer and infectious diseases. The company's lead product candidate, IMM-101, is a tumor-targeted, CD137-agonistic antibody currently being evaluated in multiple clinical trials for the treatment of solid tumors.

Key Differentiators:

• Targeting CD137: Immunome's approach focuses on targeting CD137, a co-stimulatory receptor expressed on T cells and natural killer (NK) cells. CD137 activation enhances T cell and NK cell function, leading to potent anti-tumor activity.
• Tumor-Targeted Delivery: IMM-101 is engineered with a bispecific antibody format that targets both CD137 and a tumor antigen, ensuring selective activation of immune cells within the tumor microenvironment. This targeted approach reduces systemic toxicity and enhances tumor specificity.
• Broad Therapeutic Potential: IMM-101 has demonstrated promising preclinical and early-stage clinical results in a range of solid tumors, including non-small cell lung cancer, head and neck cancer, and colorectal cancer.
• Combination Therapies: Immunome is also exploring the potential of IMM-101 in combination with other immunotherapies, including checkpoint inhibitors and adoptive cell therapies, to further enhance anti-tumor efficacy.
• Strong Intellectual Property: Immunome holds a portfolio of patents and patent applications covering its CD137-agonistic antibody technology and therapeutic applications.

Value to Patients:

• Enhanced Anti-Tumor Efficacy: IMM-101 has shown significant anti-tumor activity in preclinical and clinical settings, offering potential for improved outcomes for cancer patients.
• Reduced Toxicity: The tumor-targeted delivery mechanism of IMM-101 minimizes systemic toxicity, reducing the risk of severe adverse events associated with traditional immunotherapies.
• Broad Therapeutic Applicability: IMM-101's potential across multiple solid tumor types provides a wider range of treatment options for patients with limited treatment options.

Value to Physicians:

• Novel Therapeutic Approach: IMM-101 offers a unique and innovative approach to cancer immunotherapy, expanding the armamentarium of treatment options available to physicians.
• Targeted Therapy: The tumor-targeted delivery mechanism enhances the specificity of IMM-101, allowing for precise targeting of cancer cells and minimizing side effects.
• Personalized Treatment Options: The broad applicability of IMM-101 across different tumor types enables physicians to tailor treatment strategies to individual patient needs.

Value to Investors:

• High Unmet Medical Need: The large and growing population of cancer patients with limited treatment options represents a significant unmet medical need and a substantial market opportunity.
• Promising Clinical Data: Early-stage clinical data for IMM-101 has demonstrated promising efficacy and safety, providing strong support for its potential as a novel cancer therapy.
• Experienced Management Team: Immunome's leadership team has extensive experience in immunology, drug development, and business operations, increasing the likelihood of success.
• Strong Intellectual Property Position: Immunome's patent portfolio provides protection for its technology and potential future products, reducing competitive risks.

Risks Associated with Immunome, Inc.

Immunome, Inc. is a clinical-stage biopharmaceutical company developing novel treatments for cancer and other serious diseases. Its lead product candidate, efineptakin alfa, is a recombinant human protein that targets the interleukin-15 (IL-15) pathway. IL-15 is a cytokine that plays a role in the regulation of the immune system, and dysregulation of IL-15 has been implicated in a variety of diseases, including cancer.

Clinical Development Risk

Immunome's lead product candidate, efineptakin alfa, is still in early-stage clinical development. There is no guarantee that efineptakin alfa will be successful in clinical trials or that it will be approved for marketing by regulatory authorities.

Manufacturing Risk

Immunome does not have its own manufacturing facilities and relies on third-party manufacturers to produce its product candidates. There is a risk that these manufacturers may not be able to meet Immunome's quality or production standards, which could delay or prevent the company from bringing its product candidates to market.

Regulatory Risk

Immunome's product candidates must be approved by regulatory authorities, such as the U.S. Food and Drug Administration (FDA), before they can be marketed. There is a risk that regulatory authorities may not approve Immunome's product candidates, or that they may require additional clinical trials or other studies before approving them.

Competition Risk

Immunome faces competition from other companies developing treatments for cancer and other serious diseases. Some of these companies may have more resources or expertise than Immunome, which could give them an advantage in the development and commercialization of their product candidates.

Financial Risk

Immunome is a clinical-stage biopharmaceutical company with no approved products on the market. The company's revenue is currently limited to research and development grants and collaborations. There is a risk that Immunome may not be able to raise sufficient capital to continue its operations and develop its product candidates.

Overall

Immunome is a clinical-stage biopharmaceutical company with a promising lead product candidate. However, there are a number of risks associated with the company, including clinical development risk, manufacturing risk, regulatory risk, competition risk, and financial risk. Investors should be aware of these risks before investing in Immunome.